Bharat Biotech — which manufactures coronavirus vaccine “Covaxin” — on Thursday announced plans to ramp up production of the vaccine at its subsidiary Chiron Behring Vaccines Ltd, located in Ankleshwar, Gujarat.
The company plans to produce 200 million doses of Covaxin per annum in Good manufacturing practice (GMP) facilities already operational for production of vaccines based on inactivated vero cell platform technology, under stringent levels of GMP and biosafety.
“Product availability at Ankleshwar to commence from Q4 2021,” Bharat Biotech said in a statement.
The Company said it had already deployed multiple production lines at its Hyderabad and Bengaluru campuses, adding Chiron Behring to this line up of high containment BSL rated GMP facilities that are required to manufacture Covaxin.
“This effectively takes the volumes upto around 1 billion doses per annum, with its own established campuses specialised for manufacturing inactivated viral vaccines under the highest levels of biosafety.”
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
Source link
